Introduction
Granulocyte colony-stimulating factor (G-CSF) is the most commonly used mobilizing agent for stem cell transplantation. G-CSF-mobilized hematopoietic stem/progenitors cells (HSPCs) are associated with more rapid engraftment andFin some circumstancesFsuperior overall survival in comparison to unmanipulated bone marrow, 1 although they may be associated with increased rates of relapse in autologous grafts. 2, 3 There are several features of G-CSF-induced HSPC mobilization that need to be considered when developing a model of mobilization. First, HSPC mobilization by G-CSF is delayed, with peak levels of circulating HSPCs achieved after 5-7 days of treatment. Second, a broad spectrum of HSPCs are mobilized including hematopoietic stem cells (HSCs) as well as committed myeloid, megakaryocytic and erythroid progenitors. Finally, mobilized HSPCs have characteristic phenotypic features that are distinct from HSPCs that reside in the bone marrow under steady-state conditions. Most notably, relative to bone marrow HSPCs, a higher percentage of mobilized blood cells are in the G 0 or G 1 phase of the cell cycle, 4 and the expression of VLA-4, c-kit 5 and CXCR4
6 on their cell surface is reduced. HSPCs are selectively mobilized after the M phase of the cell cycle, providing a potential explanation for the preponderance of HSPCs in the G 0 or G 1 phase of the cell cycle in the blood. 
G-CSF mobilizes HSPCs through a hematopoietic intermediate
In addition to mature neutrophils and monocytes, the G-CSF receptor (G-CSFR) is expressed on a broad range of HSPCs including HSCs. 8 There are also reports of G-CSFR expression on endothelial cells. 9 To determine the cellular target(s) of G-CSF required for HSPC mobilization, a series of bone marrow chimeras were generated (Figure 1 ). Wild-type mice reconstituted with G-CSFR (Csf3r) À/À bone marrow cells failed to mobilize HSPCs in response to G-CSF. In contrast, G-CSFR À/À mice reconstituted with wild-type bone marrow displayed normal HSPC mobilization by G-CSF. This experiment showed that G-CSFR signaling in hematopoietic cells but not stromal cells is required for HSPC mobilization by G-CSF. As the G-CSFR is expressed on HSPCs, the simplest model suggests that G-CSF directly acts on HSPC to induce their mobilization. However, strongly arguing against this model, in mixed bone marrow chimeras containing both wild-type and G-CSFR À/À HSPCs, both types of cells were mobilized equally after G-CSF treatment. Collectively, these studies support a model in which G-CSF acts on a hematopoietic intermediary that, in turn, generates trans-acting signal(s) that lead to HSPC mobilization. 10 The nature of these trans-acting signals is still an open question.
The hematopoietic cell type(s) that mediate HSPC mobilization by G-CSF have not been defined. The G-CSFR is expressed on neutrophils, monocytes/macrophages, HSPCs, and a subset of B lymphocytes and NK cells. Although mobilization in lymphocyte-deficient mouse models is normal, 11 depletion of neutrophils using an antibody against Gr1 (Ly6C/G) results in reduced HSPC mobilization by G-CSF. 12 However, Gr1 is expressed on both neutrophils and a subset of monocytes; thus, a role for reduced monocytes in this phenotype is possible. To more directly address this issue, we generated transgenic mice that express the G-CSFR only in monocyte lineage cells by driving G-CSFR expression using the CD68 promoter on a G-CSFR À/À background (unpublished data). Despite being neutropenic at baseline, these mice display normal HSPC mobilization by G-CSF, demonstrating that G-CSFR signals in monocyte lineage cells are sufficient to induce the mobilization cascade while normal neutrophil counts are not necessary. Moreover, a recent report from Winkler et al. 13 demonstrate that depletion of monocyte lineage cells using a suicide gene or clodronate-loaded liposomes results in mobilization of HSPCs.
Monocyte lineage cells in the bone marrow include monocytes/macrophages, osteoclasts and myeloid dendritic cells. Kollet et al. 14 reported that activation of osteoclasts by injection of RANK ligand was associated with moderate HSPC mobilization. Conversely, inhibition of osteoclasts, either genetically by knocking out PTPe or by injecting mice with calcitonin, blunts the mobilization response to G-CSF. Of note, osteoclasts produce the protease cathepsin K, which can cleave CXCL12 in vitro. Together, these data suggest that osteoclasts may be the target cell that initiates HSPC mobilization by G-CSF. However, other studies indicate that osteoclasts may actually inhibit mobilization, as mice administered bisphosphonates exhibit increased mobilization in response to G-CSF, 15 even with newer generation bisphosphonates, which deplete osteoclast numbers. 13 C-kit/KitL axis C-kit receptor (often simply called 'c-kit')Ftogether with kit ligand (kitL, also known as stem cell factor or steel factor)Fis an important molecule that regulates HSPCs. All HSCs express high levels of c-kit, 16 and kitL has a crucial role in promoting their quiescence 17 and self-renewal. 18 G-CSF induces the production of proteases that cleave c-kit 19 and kitL, 20 releasing both as soluble forms. The importance of the disruption of the c-kit/kitL axis to G-CSF-induced mobilization is controversial. In support of an important role, mobilized HSPC express lower levels of c-kit than bone marrow resident HPSC, 21 and soluble levels of c-kit correlate with HSPC yield from the peripheral blood. 22 Moreover, disruption of c-kit signaling by the administration of soluble c-kit induces modest HPSC mobilization and also augments mobilization in response to G-CSF. 23 On the other hand, stimulation of c-kit signaling by administration of kitL induces robust HPSC mobilization 24 and c-kit-deficient mice have reduced G-CSF-induced mobilization. 25, 26 In addition, mice deficient in the protease matrix metalloproteinase 9 (MMP-9), which is thought to mediate kitL cleavage, mobilize normally in most strains of mice. [27] [28] [29] [30] VCAM-1/VLA-4 axis Together with its major ligand very late antigen 4 (VLA-4, also known as a4b1 integrin), vascular cell adhesion molecule 1 (VCAM-1) has a major role in anchoring HSPCs to bone marrow stromal cells 31 and regulating HSPC trafficking between the marrow and peripheral sites. 32 VLA-4 on HSPCs tethers them to VCAM-1-expressing cells, such as sinusoid endothelium and stromal reticular cells 33 and also fibronectin 34 in the extracellular matrix. Conditional deletion of VLA-4 shows that this integrin is required for normal HSPC activity. 35 Similarly, genetic ablation of VCAM-1 leads to constitutive mobilization, that is enhanced with G-CSF. 36 Moreover, antibodies to VCAM-1 or VLA-4 mobilize HSPCs in both mice 37 and humans. 38 Of potential clinical relevance, treatment with a small molecule inhibitor of VLA-4 (BIO5192) strongly mobilizes HPSC in mice. 39 G-CSF has been reported to induce proteases that cleave VCAM-1. [40] [41] However, studies in protease-deficient mice demonstrated that this cleavage is not necessary for mobilization. 27 Thus, while the VCAM-1/VLA-4 axis has a major role in HSPC homeostasis, its role in G-CSF-mediated mobilization is unclear.
CXCR4/CXCL12 axis
Together with its major receptor CXCR4, the chemokine CXCL12, also known as stromal-derived growth factor-1 (SDF-1), has a crucial role in regulating HSPC trafficking, homing 42 and maintenance. [43] [44] Its major receptor CXCR4 is expressed throughout the hematopoietic lineage from HSCs to mature cells. CXCL12 also has an additional receptor, CXCR7, 45 which is believed to act as a decoy receptor to sequester the ligand; 46, 47 however, CXCR7 does not appear to have a major role in hematopoiesis. 48 Additionally, there are several low-affinity ligands of CXCR4, such as trefoil factor 2 49 and defensin 50 but their significance in hematopoiesis is unclear. There is considerable evidence showing that CXCR4 signaling provides a key retention signal for HSPCs in the bone marrow. CXCL12 is constitutively expressed at high levels in the bone marrow and is a potent chemoattractant for HSPCs. 51, 52 In mice lacking CXCL12. 53 or CXCR4, 54 there is a failure of the migration of HSPC from the fetal liver to the bone marrow, and CXCR4 À/À bone marrow chimeras exhibit constitutive mobilization. [55] [56] Finally, treatment of humans or mice with a CXCR4 antagonist results in rapid HSPC mobilization. [57] [58] [59] Numerous lines of evidence suggest that the dominant mechanism by which G-CSF induces HSPC mobilization is through suppression of the CXCL12/CXCR4 axis. While G-CSF treatment leads to an early, transient increase in CXCL12 production, 59 prolonged treatment causes a progressive decrease in CXCL12 mRNA 60 in the bone marrow with a highly correlated concurrent drop in CXCL12 protein. [59] [60] [61] Indeed, the level of CXCL12 is inversely correlated with the degree of mobilization, with the lowest levels of CXCL12 mRNA or protein correlating with maximal mobilization.
11,59,60 G-CSF administration also is associated with decreased CXCR4 expression on mobilized HSPC.
6,61 Direct evidence for the requirement for CXCR4 signaling in HSPC mobilization comes from the study of CXCR4 À/À bone marrow chimeras. These mice, while displaying constitutive mobilization, do not further mobilize HSPC in response to G-CSF but maintain the ability to further mobilize with a VLA-4 antagonist. 56 Numerous pathways have been shown to modulate mobilization either by altering baseline CXCL12 production or modulating CXCR4 responsiveness. Pharmacologically inhibiting or genetically reducing bone marrow synthesis of catecholamines blunts mobilization by G-CSF, 11 most likely by regulating bone marrow stromal cell production of CXCL12. 62 Cell surface molecules can also modulate CXCL12 responsiveness. For example, CD26 (DPP4, dipeptidylpeptidase 4) and carboxypeptidase M are proteases present on the surface HSPCs that can cleave CXCL12, thereby inhibiting CXCR4 signaling. 63, 64 Pharmacologic or genetic inhibition of CD26 is associated with increased CXCR4 signaling and impaired G-CSF-induced HSPC mobilization. 65 Similarly, platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is an adhesion molecule expressed on both stromal and hematopoietic cells. Mice lacking PECAM-1 exhibit constitutive mobilization, perhaps because of reduced HSPC responsiveness to CXCL12. 66 Finally, a recent report from Tesio et al. 67 showed that G-CSF induces hepatocyte growth factor/c-Met signaling in HSPC, potentially contributing to mobilization by inhibiting the ability of HSPC to chemotax in response to CXCL12.
G-CSF results in a marked suppression of osteoblast lineage cells in the bone marrow
The bone marrow microenvironment has a critical role in the maintenance of HSPCs. Primitive HSPCs preferentially localize in the bone marrow either to a perivascular localization 68, 69 or near the endosteum. [70] [71] [72] [73] There is strong evidence that osteoblast lineage cells are required to maintain the 'endosteal stem cell niche'. Expansion of osteoblast lineage cells by genetic or pharmacologic means results in a concurrent expansion of HSCs. [74] [75] Conversely, ablation of mature osteoblasts using a suicide gene results in a loss of HSCs. 76 Relevant to G-CSFinduced HSPC mobilization, osteoblast lineage cells are a source of CXCL12 in the bone marrow. 59 with the death of half of all osteoblasts because of apoptosis. 80 Moreover, the surviving osteoblasts reduce their expression of CXCL12 mRNA by approximately one-half. 60 Interestingly, osteoblast suppression is a common feature of HSPC mobilization by other cytokines, including Flt3 ligand and kitL. 56 Though alterations in osteoblast lineage cells are likely to be a key step in G-CSF-induced mobilization, the mechanisms by which this leads to HSPC egress from the bone marrow remain to be elucidated.
Neutrophil-derived proteases are induced after G-CSF treatment
After G-CSF treatment, bone marrow myeloid cells release a wide number of proteases such as MMP-9, cathepsin G and neutrophil elastase, 41 thus shifting the bone marrow to a more proteolytic environment. These proteases were suggested to cause mobilization by cleaving a variety of HSPC supporting molecules, such as kitL, 81 VCAM-1, 40 CXCL12 61,64 and its receptor CXCR4. 61 Serine protease inhibitors known as serpins have also been implicated in mobilization. After G-CSF, the levels of serpin1 and serpin3 are reduced in the marrow, 82 thus making the marrow environment more proteolytic. In fact, administration of serpin1a inhibits interleukin (IL)-8-mediated mobilization, 83 although the role serpins play in G-CSF-mediated mobilization has yet to be defined.
The contribution of neutrophil proteases to G-CSF-induced HSPC mobilization is controversial and is confounded by different groups using different strains of mice. Depletion of neutrophils 84 or administration of anti-MMP-9 antibodies 85 inhibits the rapid mobilization seen in response to the chemokine IL-8. Moreover, one report suggested that MMP-9-deficient mice have a mobilization defect in response to G-CSF. 81 Similarly, systemic administration of inhibitors to MMP-9 or neutrophil elastase inhibits G-CSF-mediated mobilization. 12, 59 However, the role that proteases have in mobilization was thrown into question when it was shown that MMP-9-deficient mice mobilize normally in response to IL-8, 27 and other groups were unable to reproduce the mobilization defect previously seen in these mice using G-CSF. [27] [28] [29] [30] Moreover, mice lacking combinations of neutrophil elastase, cathepsin G, or MMP-9 mobilize normally even in the presence of a broad-spectrum metalloproteinase inhibitor. 27 Collectively, these data suggest that while not absolutely required, neutrophil proteases may augment G-CSF-induced HSPC mobilization in the appropriate genetic background.
Regulation of HSPC mobilization by uPAR
The urokinase-type plasminogen activator receptor (uPAR) is most well known for binding and activating urokinase plasminogen activator (uPA, commonly known as urokinase), which cleaves plasminogen to plasmin during the clotting cascade. However, uPAR also binds to integrins and G-proteincoupled receptors and initiates downstream signaling cascades to regulate cellular processes, such as cell adhesion and migration. 86 A subset of HSPCs expresses uPAR on their surface, which helps tether them to the niche via interactions with VLA-4. 87 On G-CSF treatment, uPAR is cleaved from the cell surface by plasmin 87 and released into the extracellular space, wherein it is subsequently proteolytically cleaved into smaller fragments. 88 Selleri et al. 89 suggest that
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Mechanisms of G-CSF mediated HSPC mobilization AM Greenbaum and DC Link uPAR cleavage might contribute to HSPC mobilization by: (1) disrupting uPAR's interaction with integrins; (2) inhibiting CXCR4 signaling by soluble uPAR fragments; and (3) inducing HPSC migration by soluble uPAR fragments. Consistent with this model, genetic or pharmacologic approaches leading to increased plasmin activation (resulting in increased uPAR cleavage) are associated with enhanced G-CSF-induced HPSC mobilization. 90 
Complement regulates mobilization
Recent studies implicate the complement system in the regulation of HSPC trafficking in the bone marrow. The complement component C3 is synthesized by bone marrow stromal cells, 91 and on G-CSF administration, C3 is cleaved into C3a and C3b. 92 HSPCs express the receptor for C3a, and binding of C3a augments their chemotaxis to CXCL12. This suggests that C3a may negatively regulate mobilization. Indeed, mice lacking either C3a or its receptor have enhanced mobilization in response to G-CSF, as do mice treated with an inhibitor of C3a receptor. 93 In addition to C3, other complement components such as C5 are also acted on by G-CSF administration. In contrast to C3, C5 likely positively regulates mobilization, as C5-deficient mice mobilize poorly, 93 and activation of C5 correlates with better mobilization in humans. 94 This is not a direct effect of C5 on HSPCs, as they do not express C5a receptor, but it may be related to its effect on neutrophil activation. 95 In addition, formation of the membrane attack complex is believed to lead to the lysis of red blood cells, which releases the lipid sphingosine-1-phosphate, which is a potent chemoattractant for HSPCs. 96 How complement is activated during G-CSF is not entirely clear, but evidence suggests that it may be via antibody activation of complement. Immunoglobulin-deficient mice strains including RAG2 À/À , SCID or Jh mice mobilize poorly in response to G-CSF, a phenotype rescued by injected immunoglobulin G. 93 However, this mechanism is not entirely proven, as others have shown that immunoglobulindeficient RAG1
À/À and IL-7Ra À/À mice mobilize normally with G-CSF.
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Open questions/future directions
The precise subtype of monocyte lineage cells in the bone marrow and the nature of the trans-acting signals that regulate osteoblast lineage cells are currently unknown. The identification of these trans-acting factors may provide novel targets to modulate HSC function and/or bone metabolism. The subtype of osteoblast lineage cells that regulates HSPC trafficking also has not been defined. Indeed, there is evidence that mature osteoblasts may not be the major source of CXCL12 protein in the marrow. Sugiyama et al. 69 reported the presence of CXCL12-abundant reticular cells that were scattered throughout the bone marrow and were in direct contact with most HSCs. 69 Moreover Méndez-Ferrer et al. 97 recently reported a novel population of nestin-expressing mesenchymal stem cells, which regulate HSCs, produce CXCL12 and are regulated by G-CSF. Studies to characterize the effect of G-CSF administration on different bone marrow stromal cell populations may be informative.
It is also unclear how disruption of CXCR4 signaling in HPSCs leads to their egress from the bone marrow. We recently 
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AM Greenbaum and DC Link reported that expression of the CXCL2 chemokine by bone marrow endothelial cells may provide a second signal directing neutrophil migration from the bone marrow into the circulation. 98 This suggested a 'tug-of-war' model in which CXCL2 expression by endothelial cells (directing release) and CXCL12 expression by endosteal osteoblasts (directing retention) antagonistically regulate neutrophil release from the bone marrow. Whether similar signals direct HPSC egress is currently unknown. Of note, Ratajczak et al. 96 recently reported that high levels of sphingosine-1-phosphate generated in the blood during G-CSF administration by complement activation may contribute to HPSC migration into the blood.
In summary, though our understanding of the molecular mechanisms contributing to HSPC mobilization by G-CSF has improved, there remain many important unanswered questions. Future research in this area has the potential of advancing our understanding of the stem cell niche, regulation of HSC function/trafficking and bone metabolism and may lead to novel strategies to increase HSPC mobilization yields and enhance HSPC homing and engraftment following transplantation.
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